Microfluidic Chip Method Versus Density-gradient Centrifugation Method in IVF

Infertility Clinical Trial

Official title:

A Randomized Double-blind Controlled Study of the Cumulative Live Birth Rate of IVF Following Sperm Preparation by Microfluidic Chip Method Versus Density-gradient Centrifugation Method

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06005311
• Other study ID #: UW 23-293
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2024
• Est. completion date: December 31, 2027

Study information

• Verified date: May 2024
• Source: The University of Hong Kong
• Contact: YU WING TONG, MBBS
• Phone: 92707722
• Email: ptong[@]connect.hku.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Infertile patients attending IVF treatment at the Centre of Assisted Reproduction and Embryology, Queen Mary Hospital and Kwong Wah Hospital will be recruited during ovarian stimulation for IVF. Subsequently, they will be randomly assigned on the day of oocyte retrieval by a laboratory staff into one of the following two groups: (1) the microfluidic chip group and (2) the density gradient group for sperm preparation and subsequent use in fertilization. Other IVF procedures will be the same as our usual practice. Both patients and clinicians were blinded from the group allocation i.e. a double blind study. The primary outcome is the cumulative live birth rate defined as the number of pregnancies leading to live birth within 6 months of randomisation.

Description:

The trial will compare the use of a microfluidic chip with the use of density gradient centrifugation for sperm preparation.

The hypothesis of the study is that the use of the microfluidic chip will improve the cumulative live birth rate of IVF compared to the density gradient method.

The trial will be conducted at the Centre of Assisted Reproduction and Embryology at Queen Mary Hospital and Kwong Wah Hospital. Infertile patients undergoing IVF treatment will be recruited during ovarian stimulation. They will be randomly assigned to one of two groups: the microfluidic chip group or the density gradient group. Both the patients and the clinicians will be blinded to the group allocation.

The inclusion criteria for the study are infertile women aged under 43 years undergoing ovarian stimulation for IVF. The exclusion criteria include women undergoing certain genetic testing, male factor infertility requiring surgical sperm retrieval, the use of donor oocytes and spermatozoa, certain uterine conditions, previous participation in the study, and participation in other randomized trials.

The eligible women will undergo standard IVF procedures, including ovarian stimulation, monitoring of follicle growth, trigger for oocyte retrieval, and oocyte retrieval itself. On the day of oocyte retrieval, the women will be randomly assigned to either the microfluidic chip group or the density gradient group for sperm preparation.

Semen samples will be collected on the day of oocyte retrieval and evaluated according to standard guidelines. Sperm DNA damage will also be assessed using an alkaline single-cell gel electrophoresis assay. Depending on the randomization, the sperm samples will be prepared either using the microfluidic chip or the density gradient centrifugation method.

After sperm preparation, oocytes will be fertilized using either conventional insemination or intracytoplasmic sperm injection. Fertilization will be confirmed by the presence of two pronuclei. Fresh embryo transfer will be performed 2-5 days after egg retrieval, and luteal phase support will be given. Excessive good quality embryos or blastocysts will be cryopreserved for future use.

For frozen embryo transfer, embryos or blastocysts will be replaced in subsequent natural or hormonal replacement cycles. Pregnancy will be confirmed by a urine pregnancy test, and transvaginal ultrasound will be performed to confirm viability and the number of fetuses.

Follow-up will be conducted to retrieve pregnancy and delivery data. The cumulative live birth rate will be calculated, and pregnancy outcomes, including birth weights and obstetric complications, will be recorded and compared between the two groups.

The study will continue until all cryopreserved embryos or blastocysts are used or until the participants become pregnant within 6 months after randomization. The pregnancy complications and congenital abnormalities will be monitored through hospital records or patient contact.

Ultimately, the study aims to determine whether the use of the microfluidic chip improves the cumulative live birth rate of IVF compared to the density gradient method.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1136
• Est. completion date: December 31, 2027
• Est. primary completion date: June 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 43 Years

Eligibility

Inclusion Criteria:

• Infertile women aged <43 years at the time of ovarian stimulation for IVF

Exclusion Criteria:

• Women undergoing preimplantation genetic testing monogenic diseases, structural rearrangement of chromosomes or aneuploidy;

• Male factor requiring surgical sperm retrieval such as microscopic epididymal sperm aspiration and testicular sperm extraction;

• Use of donor oocytes and spermatozoa;

• Submucosal fibroid or hydrosalpinx shown on pelvic scanning and not surgically treated;

• Women who had been recruited into this study before and

• Women joining other randomized trials

Related Conditions & MeSH terms

• Infertility

Intervention

Device:
• Microfluidic chip
The Sperm Separation Device - ZyMot Multi 850µL (ZyMot Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 µL of the semen sample will be inserted into the inlet port of the device and 750 µL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 µL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.
• Density-gradient centrifugation
After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.

Locations

Country	Name	City	State
China	Department of Obstetrics and Gynaecology	Hong Kong	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Professor Ernest Hung-Yu Ng

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cumulative live birth rate	cumulative live birth rate defined as the number of pregnancies leading to live birth within 6 months of randomisation.	within 6 months of randomisation.
Secondary	Live birth beyond 22 weeks of gestation per the first embryo transfer or FET	Live birth beyond 22 weeks of gestation per the first embryo transfer or FET	3 years
Secondary	Positive urine pregnancy test per the first embryo transfer or FET	Positive urine pregnancy test per the first embryo transfer or FET	3 years
Secondary	Clinical pregnancy per the first embryo transfer or FET defined as presence of intrauterine gestational sac on scanning at gestational week 6.	Clinical pregnancy per the first embryo transfer or FET defined as presence of intrauterine gestational sac on scanning at gestational week 6.	3 years
Secondary	Ongoing pregnancy rate as presence of a fetal pole with pulsation at 8-10 weeks of gestation	Ongoing pregnancy rate as presence of a fetal pole with pulsation at 8-10 weeks of gestation	3 years
Secondary	Miscarriage defined as a clinically recognized pregnancy loss before the 22 weeks of pregnancy and whose denominator is the clinical pregnancy.	Miscarriage defined as a clinically recognized pregnancy loss before the 22 weeks of pregnancy and whose denominator is the clinical pregnancy.	3 years
Secondary	Multiple pregnancy: presence of more than one intrauterine sac at 6 weeks of gestation	Multiple pregnancy: presence of more than one intrauterine sac at 6 weeks of gestation	3 years
Secondary	Ectopic pregnancy rate	Ectopic pregnancy rate	3 years